Todos Medical - Full Color Logo
  • R&D Pipeline
    • Proprietary Diagnostics
      • Videssa® Breast: Cancer Blood Test
      • LymPro™: Alzheimer's Blood Test
      • TolloTest™: Coronavirus 3CL Protease Test
      • TBIA: AI Cancer Platform
    • Antiviral Drug Development
      • Tollovir™: 3CL Protease Inhibitor
  • Products & Services
    • Lab Solutions
      • Provista Diagnostics: CLIA/CAP Lab
      • COVID Testing: Lab Supplies & Automated Solutions
    • Dietary Supplement
      • Tollovid™: 3CL Protease Inhibitor
  • Insights
    • Publications
    • News & Media
    • Downloads
    • How It Works: 3CL Protease Inhibitors
    • Case Study: Lab Automation
  • Investors
  • About
    • Management Team
    • Board of Directors
    • Advisors
    • Career Opportunities
    Add a button link here
    Contact Us

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Governance Documents
    • News & Events

    • Press Releases
    • IR Calendar
    • Email Alerts
    Dec 16, 2021 12:25pm EST

    Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19

    Dec 13, 2021 7:30am EST

    Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes

    Dec 10, 2021 12:29pm EST

    Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST

    Dec 07, 2021 9:19am EST

    Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics

    Dec 06, 2021 3:14pm EST

    Todos Medical to Present at Upcoming Emerging Growth Conference

    Dec 02, 2021 6:00am EST

    Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

    Dec 01, 2021 4:05pm EST

    Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

    Nov 30, 2021 8:38am EST

    Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant

    Nov 29, 2021 9:08am EST

    Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

    Nov 24, 2021 2:00am EST

    Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

    • arrow_back
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • …20
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Company Profile
    • Contacts
    • RSS News Feed

    Todos Medical - Full Color-1

     

    About Us

    Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.

    OTCQB: TOMDF

    Contact Us

    Todos Medical Ltd.
    121 Derech Menachem Begin

    30th Floor
    Tel Aviv, Israel 6701203
    Phone: +972-73-207-7259

    Todos Medical U.S.A.
    40 Wall Street, Suite 2702

    New York, NY 10005
    Phone: +1-917-983-4229

    Sign Up

    Follow us on Twitter Follow us on Facebook Follow us on LinkedIn
    © 2022 Todos Medical. All rights reserved.